Prognostic value of GRIM-19, NF-κB and IKK2 in patients with high-grade serous ovarian cancer.

Keywords

Debulking, Medicine, Internal medicine, Oncology, Ovarian cancer

References

• Promotion of DNA repair by nuclear IKKβ phosphorylation of ATM in response to genotoxic stimuliErna — 2013
• GRIM-19 expression is a potent prognostic marker in colorectal cancer.Miao Hao, Zhenbo Shu, Hongyan Sun — 2015
• Upregulation of GRIM-19 inhibits the growth and invasion of human breast cancer cells.Wei Zhang, Ye Du, Tong Jiang — 2015
• Expression of classical NF‐κB pathway effectors in human ovarian carcinomaSilvia Darb‐Esfahani, Bruno V. Sinn, Wilko Weichert — 2010
• Identification of GRIM-19, a Novel Cell Death-regulatory Gene Induced by the Interferon-β and Retinoic Acid Combination, Using a Genetic Approach*Jon E. Angell, Daniel J. Lindner, Paul Shapiro — 2000
• Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.Jennifer Williams, Peter C. Lucas, Kent A. Griffith — 2005
• p53 stabilization is decreased upon NFκB activationVinay Tergaonkar, Matthew P. Pando, Omid Vafa — 2002
• GRIM‐19, a death‐regulatory gene product, suppresses Stat3 activity via functional interactionChengchen Lufei, Jing Ma, Guochang Huang — 2003
• Proteasome Inhibition Increases Recruitment of IκB Kinase β (IKKβ), S536P-p65, and Transcription Factor EGR1 to Interleukin-8 (IL-8) Promoter, Resulting in Increased IL-8 Production in Ovarian Cancer Cells*Bipradeb Singha, Himavanth R. Gatla, Subrata Manna — 2013
• TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens.Izabela Ziółkowska-Seta, Radosław Mądry, Ewa Kraszewska — 2009
• Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.Suk‐Joon Chang, Melissa Hodeib, Jenny Chang — 2013
• Expression and clinical significance of GRIM-19 in lung cancerXiaoyun Fan, Zi‐Feng Jiang, Li Cai — 2012
• Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological featuresJaime Prat — 2012
• Survey on Knowledge, Attitudes, and Training Needs of Italian Residents on Genetic Tests for Hereditary Breast and Colorectal CancerNikola Panić, Emanuele Leoncini, Paolo Di Giannantonio — 2014
• Immunohistochemical analysis of NF‐κB signaling proteins IKKε, p50/p105, p52/p100 and RelA in prostate cancersSeong Il Seo, Sang Yong Song, Mi Ran Kang — 2009
• NF-kB in development and progression of human cancerXavier Dolcet, David Llobet‐Navàs, Judit Pallarés — 2005
• "Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?Alison Davis, Anna V. Tinker, Michael Friedländer — 2014
• Cytokine-induced tumor suppressors: a GRIM storyDhan V. Kalvakolanu, Shreeram C. Nallar, Sudhakar Kalakonda — 2010
• Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical StudyIoanna Giopanou, Vasiliki Bravou, Panagiotis Papanastasopoulos — 2014
• NF-κB transcription factors are co-expressed and convey poor outcome in ovarian cancerChristina M. Annunziata, Helene Tuft Stavnes, Lilach Kleinberg — 2010

Cited by

• Clinico‑morphological aspects and new immunohistochemistry characteristics of ovarian high‑grade serous carcinomaManuela Popa, Adelina BIRCEANU COROBEA, Monica Mihaela Cîrstoiu — 2018
• OLFM4 Enhances STAT3 Activation and Promotes Tumor Progression by Inhibiting GRIM19 Expression in Human Hepatocellular CarcinomaYosuke Ashizawa, Satoshi Kuboki, Hiroyuki Nojima — 2019
• Interaction of M2 macrophages and endometrial cells induces downregulation of GRIM-19 in endometria of adenomyosis.Bingyu Wang, Yang Yang, Xiaohui Deng — 2020
• Müsinöz Olmayan Akciğer Adenokarsinomlarında Caspase-3 ve GRIM-19 Ekspresyonu ile Bu Proteinlerin Klinikopatolojik ÖnemiAlev Ok Atılgan, Merih Tepeoğlu, Eda Yılmaz Akçay — 2023

Related papers

• Abstract 2056: Identification of microscopic ovarian tumor foci utilizing a novel imaging device in a murine ovarian cancer model, an opportunity to improve optimal cytoreductionYoung-Jeong Na, Tim Tak Kwok, Christopher S. Awtrey — 2014
• Relationship of Preoperative Serous CA125 with Clinicopathological Features and Prognosis in Patients with Epithelial Ovarian CancerBin Liu — 2013
• Mixed serous—endometrioid carcinoma of the uterus: pathologic and cytopathologic analysis of a high-risk endometrial carcinomaKatherine E. Williams, E. D. Waters, Robert Woolas — 1993
• Biologically-Targeted Detection of Primary and Micro-Metastatic Ovarian CancerTracy Liu, Jocelyn M. Stewart, Thomas D. MacDonald — 2013
• Micropapillary Serous Carcinoma: The Solution to the Ovarian Borderline Tumor ConundrumJeffrey D. Seidman, Marisa R. Varallo — 2007
• Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinomaM. Herman Chui, Deyin Xing, Felix Zeppernick — 2019
• High‐grade ovarian serous carcinoma exhibits significantly higher p16 expression than low‐grade serous carcinoma and serous borderline tumourCiaran O’Neill, Hilary A. McBride, L E Connolly — 2007
• 37. Retrospective review of 27 cases reported as low grade serous ovarian carcinomaMarsali Newman, Kerryn Ireland‐Jenkin — 2019
• Borderline With Bad Behavior: An Unusual Low-grade Serous Carcinoma With Dedifferentiation From a Serous Borderline Tumor.Amanda Strickland, Kruti P. Maniar, Edward J. Tanner — 2023
• The Anterior Gradient Homolog 3 (AGR3) Gene Is Associated with Differentiation and Survival in Ovarian CancerErin R. King, Celestine S. Tung, Yvonne T.M. Tsang — 2011